What Are Crosslinkers in Antibody Bioconjugation?
A crosslinker is a bifunctional chemical reagent containing two reactive groups separated by a spacer arm. In antibody bioconjugation, crosslinkers serve as the covalent bridge that permanently links an antibody to a target molecule such as a fluorophore, an enzyme, a drug, a biotin moiety, or another protein. The primary role of the crosslinker is to control the spatial orientation and stoichiometry of the resulting conjugate while minimizing damage to antibody structure and antigen-binding activity.
The concept of chemical crosslinking originated in protein chemistry, where reagents such as glutaraldehyde and formaldehyde were used to fix protein structures and stabilize protein-protein interactions. Modern crosslinkers are highly refined molecules designed with tunable spacer lengths, cleavable or non-cleavable linkages, and reactive groups that target specific amino acid side chains on the antibody surface. The evolution from simple aldehyde-based fixation to sophisticated heterobifunctional reagents with orthogonal reactivity has enabled the precision bioconjugation workflows that underpin contemporary ADC development, site-specific antibody labeling, and quantitative structural biology.
In the context of antibody bioconjugation specifically, crosslinkers address a fundamental challenge: antibodies and their payloads are chemically distinct, often lacking mutually reactive groups. A crosslinker provides a controlled chemical interface, first reacting with the antibody at one functional group (e.g., a lysine amine or a cysteine thiol) and then with the payload at a different reactive site. The spacer arm between these two reactive ends sets the physical distance between the antibody and the conjugated molecule, which can profoundly influence conjugate performance by modulating steric accessibility, binding affinity, and in the case of ADCs, linker-dependent cytotoxicity.
Core functionCrosslinkers covalently join two molecular entities, one of which is the antibody, through specific reactive groups that target lysines, cysteines, carboxylates, or carbohydrates. Unlike simple labeling reagents, crosslinkers introduce a defined spacer that can be engineered for solubility, length, cleavability, or bioorthogonal reactivity.
Why crosslinkers matterThe choice of crosslinker determines whether conjugation is random or oriented, whether the conjugate retains full biological activity, and whether the linker itself contributes to product properties such as aqueous solubility, in vivo stability, or the ability to release payload inside a target cell. In ADC development, linker selection is as critical as antibody and payload selection.
Key design elementsEvery crosslinker is defined by three structural features: the identity of its two reactive groups, the length and chemical character of its spacer arm (hydrophilic PEG-like or hydrophobic alkyl), and the presence of any cleavable motifs such as disulfide bonds or protease-sensitive peptide sequences.
Scope of this guideThis guide covers homobifunctional (amine-to-amine, thiol-to-thiol), heterobifunctional (amine-to-thiol, amine-to-carboxyl, and photoreactive), and zero-length crosslinkers, with practical guidance on reagent selection, reaction optimization, and troubleshooting for antibody bioconjugation applications.
Classification of Crosslinker Reagents
Crosslinkers are classified by the relationship between their two reactive groups. Homobifunctional reagents carry two identical reactive ends, heterobifunctional reagents carry two different reactive ends, and zero-length reagents activate existing functional groups to form a direct bond without introducing a linker scaffold. Each class offers distinct advantages and limitations depending on the nature of the antibody, the payload, and the desired conjugation outcome.
Homobifunctional crosslinkers are the simplest in concept: both ends target the same chemical functionality, typically primary amines or free thiols. This means that a single reagent can crosslink two lysine residues, two cysteine residues, or any two molecules that present the same reactive group. Heterobifunctional crosslinkers are more sophisticated and enable greater control because their two different reactive groups can be addressed sequentially, first to the antibody and then to the payload, minimizing undesired homodimerization or intramolecular crosslinking. Zero-length reagents represent a special case where the crosslinker itself does not persist in the final conjugate; instead, it activates a carboxyl group that then reacts with an amine to form a direct amide bond.
| Feature | Homobifunctional | Heterobifunctional | Zero-Length |
|---|
| Reactive ends | Two identical groups (e.g., two NHS esters) | Two different groups (e.g., NHS ester + maleimide) | No persistent linker; activates carboxyl for direct amide bond |
| Conjugation strategy | One-step; mix with both reactants simultaneously | Two-step sequential: react with antibody first, then add payload | One-step; EDC activates carboxylate, NHS stabilizes intermediate |
| Orientation control | None; random orientation | Precise; defines which end attaches to antibody and which to payload | Limited; depends on accessible carboxyl/amine pairs |
| Spacer arm | Yes; variable length (6-35 angstroms) | Yes; tunable length, often with PEG or cleavable segments | No; direct peptide bond with zero added atoms |
| Risk of homodimerization | High; antibody-antibody crosslinking is common | Low; sequential addition minimizes unwanted side products | Moderate; depends on stoichiometry and local concentration |
| Typical applications | Protein complex stabilization, immunoprecipitation, structural biology | ADC assembly, controlled antibody-enzyme conjugation, site-specific labeling | Hapten-carrier conjugation, enzyme-antibody coupling, peptide conjugation |
Homobifunctional Crosslinkers: Amine-to-Amine and Thiol-to-Thiol
Homobifunctional crosslinkers are the most established reagents in protein chemistry, used for decades to stabilize protein complexes, immobilize antibodies on solid supports, and generate antibody-enzyme conjugates for immunoassays. Their defining feature is identical reactivity on both ends, which simplifies the conjugation protocol but introduces complexity in product composition because every reactive group on the antibody can potentially participate in crosslinking.
The most widely used homobifunctional reagents target primary amines via N-hydroxysuccinimide (NHS) ester chemistry. Bis(sulfosuccinimidyl) suberate (BS3) and its non-sulfonated analog disuccinimidyl suberate (DSS) are the prototype NHS-ester homobifunctional crosslinkers. Both contain an 11.4-angstrom suberate spacer with an NHS ester at each end, enabling rapid reaction with lysine side chains and protein N-termini at pH 7.2-8.5. BS3 is water-soluble due to its sulfonate groups and is membrane-impermeable, making it suitable for cell-surface protein crosslinking. DSS is hydrophobic and membrane-permeable, enabling intracellular crosslinking applications. The choice between BS3 and DSS depends primarily on whether the antibody or its target is accessible from the extracellular space.
Other amine-reactive homobifunctional reagents vary in spacer arm length and chemistry. Disuccinimidyl glutarate (DSG) provides a shorter 7.7-angstrom spacer, which produces a tighter crosslink and is useful for identifying close-contact residues in protein interaction studies. Disuccinimidyl tartrate (DST) contains a diol that can be cleaved by periodate, making it useful as a reversible crosslinker for applications where the crosslinked product must be dissociated after analysis. Ethylene glycol bis(succinimidyl succinate) (EGS) features a 16.1-angstrom PEG-like spacer with improved aqueous solubility and cleavability by hydroxylamine at pH 8.5. For thiol-to-thiol crosslinking, bismaleimidohexane (BMH) and 1,4-bis-maleimidobutane (BMB) provide homobifunctional reactivity toward free cysteine residues, though these are used less frequently with antibodies because antibody thiols are typically buried within disulfide bonds.
| Crosslinker | Reactive Group | Spacer (angstroms) | Solubility | Cleavable | Typical Use |
|---|
| BS3 | Sulfo-NHS ester x2 | 11.4 | Water-soluble | No | Cell-surface protein crosslinking, antibody immobilization |
| DSS | NHS ester x2 | 11.4 | DMSO-soluble | No | Intracellular crosslinking, protein interaction mapping |
| DSG | NHS ester x2 | 7.7 | DMSO-soluble | No | Close-contact crosslinking, short-range interaction capture |
| DST | NHS ester x2 | 6.4 | DMSO-soluble | Yes (periodate) | Reversible crosslinking; dissociate for MS analysis |
| EGS | NHS ester x2 | 16.1 | DMSO-soluble | Yes (hydroxylamine) | Long-range crosslinking, reversible complex stabilization |
| BMH | Maleimide x2 | 13.0 | DMSO-soluble | No | Thiol-to-thiol crosslinking, protein complex stabilization |
When using homobifunctional crosslinkers with antibodies, careful control over the molar ratio of crosslinker to antibody is essential. Because IgG molecules contain 30-90 surface-accessible lysines and multiple copies of the antibody are present in solution, BS3 or DSS can simultaneously react with two lysines on the same antibody (intramolecular crosslinking), two lysines on different antibodies (intermolecular crosslinking producing antibody dimers or oligomers), or one lysine on the antibody and one on the payload. The product mixture from homobifunctional conjugation is therefore inherently heterogeneous, and purification steps such as size-exclusion chromatography are often required to isolate the desired conjugate species from high-molecular-weight aggregates and unreacted starting materials.
Heterobifunctional Crosslinkers: Amine-to-Thiol and Beyond
Heterobifunctional crosslinkers have transformed antibody bioconjugation by enabling sequential, oriented coupling reactions where the antibody and its payload are conjugated in a defined manner. Unlike homobifunctional reagents that expose both reactive ends simultaneously, heterobifunctional crosslinkers can be pre-reacted with the antibody through one functional group, purified to remove excess reagent, and then reacted with the payload through the second group. This two-step workflow dramatically reduces undesired side products and gives the researcher control over conjugate architecture.
The most prominent class of heterobifunctional crosslinkers combines an NHS ester for amine reactivity with a maleimide for thiol reactivity. The prototype is succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) and its water-soluble sulfonated analog Sulfo-SMCC. In a typical conjugation workflow, SMCC is first reacted with the antibody at pH 7.2-7.5, where the NHS ester acylates accessible lysine residues to form stable amide bonds. After removal of excess SMCC by desalting, the maleimide-activated antibody is combined with a thiol-containing payload such as a cysteine-engineered protein, a thiol-modified drug-linker, or a reduced peptide. The maleimide-thiol reaction proceeds rapidly and with high specificity at pH 6.5-7.5, producing a thioether linkage.
The SMCC spacer is a cyclohexane ring that imparts rigidity and a defined inter-molecular distance of approximately 8.3 angstroms. For applications requiring a longer or more flexible spacer, related reagents with extended PEG spacers are available. Succinimidyl-([N-maleimidopropionamido]-PEG) ester compounds, often abbreviated as SM(PEG)n, contain polyethylene glycol segments of defined length that increase solubility, reduce non-specific protein adsorption, and provide greater spatial separation between the antibody and payload. These extended spacers are particularly valuable for antibody-enzyme conjugates, where steric hindrance from a rigid short linker can reduce enzymatic activity.
Another important subclass of heterobifunctional reagents incorporates a photoreactive group, typically a phenyl azide or benzophenone, alongside an NHS ester, maleimide, or other chemically reactive group. Photoreactive crosslinkers such as sulfosuccinimidyl-2-[7-azido-4-methylcoumarin-3-acetamido]ethyl-1,3-dithiopropionate (SAED) or sulfosuccinimidyl-4-azidosalicylamido-hexanoate (Sulfo-SASD) enable a unique workflow: the antibody is first derivatized through the chemical group, and then the photoreactive end is activated by UV light in the presence of the binding partner. This approach captures transient or weak protein interactions that would not survive the longer incubation times required for purely chemical crosslinking, making photoreactive heterobifunctional reagents invaluable for studying antibody-antigen interfaces and dynamic protein complexes.
SMCC / Sulfo-SMCCNHS ester-maleimide heterobifunctional. NHS end reacts with antibody lysines; maleimide end reacts with payload thiols. Spacer is 8.3-angstrom cyclohexane. Sulfo-SMCC is water-soluble; ideal for aqueous antibody conjugation without organic co-solvents.
SM(PEG)n seriesNHS ester-maleimide with PEG spacers of 2 to 24 ethylene glycol units. Extended reach (up to ~95 angstroms) reduces steric hindrance. PEG character improves conjugate solubility and reduces aggregation during conjugation.
Photoreactive heterobifunctionalCombine NHS ester or maleimide with phenyl azide, benzophenone, or diazirine. Chemical group attaches to antibody first; UV activation captures transient interactions. Ideal for antibody-antigen interface mapping and interaction proteomics.
Cleavable heterobifunctionalInclude disulfide (reducible by DTT/TCEP), hydrazone (acid-labile), or peptide (protease-cleavable) motifs. Enable release of conjugated payload under defined conditions. Critical for ADC linker design where intracellular drug release is required.
Zero-Length Crosslinkers: EDC and Carbodiimide Chemistry
Zero-length crosslinkers differ fundamentally from homobifunctional and heterobifunctional reagents because they do not become part of the final conjugate. Instead, they activate a carboxyl group on one molecule for direct reaction with a primary amine on another, forming a native amide bond with no intervening spacer atoms. The most important zero-length crosslinking system in antibody bioconjugation is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) used in combination with N-hydroxysuccinimide (NHS) or sulfo-NHS.
In the EDC/NHS reaction, EDC first reacts with a carboxylate group on the antibody (or payload) to form an O-acylisourea intermediate. This intermediate is unstable in aqueous solution and hydrolyzes rapidly, so NHS is included to convert it to a more stable NHS ester. The resulting NHS ester then reacts with a primary amine on the partner molecule to form a stable amide bond. The net result is a direct carboxyl-to-amine conjugation with zero added linker atoms. Because EDC and NHS are consumed as activating reagents rather than incorporated into the product, the conjugated molecules remain in close physical contact, which is advantageous for applications where a short distance between the antibody and its payload is desired.
The EDC/NHS system is widely used for hapten-carrier conjugation where small-molecule haptens containing carboxylic acid groups are coupled to lysine-rich carrier proteins, and for enzyme-antibody conjugation where carboxyl groups on one protein react with amines on the other. However, zero-length conjugation presents several challenges when applied to antibodies. Because both the antibody and many payloads contain both carboxyl and amine groups, the reaction can produce antibody-antibody dimers, payload-payload oligomers, and intramolecular crosslinks if not carefully controlled. The pH must be maintained in the 5.0-6.0 range for optimal EDC activation of carboxylates, which is slightly below the physiological pH at which antibodies are most stable. Prolonged exposure to EDC at low pH can promote antibody aggregation.
EDC mechanismEDC activates carboxylates to O-acylisourea. NHS converts this to a stable NHS ester. The NHS ester reacts with primary amines to form amide bonds. Both EDC and NHS are removed during purification and do not remain in the conjugate.
Key advantageZero spacer atoms mean the antibody and payload are in direct contact, which can maximize Förster resonance energy transfer (FRET) efficiency in fluorescence applications and minimize conformational flexibility for structural studies.
LimitationsReaction pH (5.0-6.0) can compromise antibody stability. Cannot control which carboxyl-amine pairs react. Produces heterogeneous products when both partners contain multiple reactive groups. Requires careful stoichiometric optimization.
ApplicationsHapten-protein conjugation for antibody generation, enzyme-antibody coupling for immunoassays, peptide-antibody conjugation, and nanoparticle functionalization where close spacing between antibody and surface is favorable.
How to Select the Right Crosslinker for Antibody Conjugation
Selecting the appropriate crosslinker requires balancing multiple interdependent factors: the available reactive groups on the antibody and payload, the desired degree of homogeneity, the tolerance for spacer length and composition, and practical considerations such as reagent solubility and buffer compatibility. A systematic approach that evaluates these parameters before the first bench experiment can prevent costly failures and save months of optimization.
The first decision point is whether the conjugation requires a homogeneous, oriented product. If the goal is to produce a research-grade fluorescent antibody for flow cytometry, where some heterogeneity is acceptable, a simple one-step reaction with an amine-reactive reagent may suffice. If the goal is to develop a preclinical ADC where drug-to-antibody ratio, product homogeneity, and linker stability are critical parameters, a heterobifunctional crosslinker with sequential addition steps, potentially combined with engineered cysteine or enzymatic conjugation sites, is the appropriate choice.
The second factor is the chemistry of the payload. If the payload contains a free thiol, an NHS ester-maleimide heterobifunctional reagent such as SMCC enables direct antibody-to-payload conjugation. If the payload is a carboxyl-containing hapten, EDC/NHS zero-length chemistry may be preferred. If the payload lacks convenient reactive groups, the crosslinker must be chosen to introduce a reactive handle on either the antibody or the payload prior to conjugation. In many cases, the payload is first derivatized with a linker containing a thiol or amine group, and then the derivatized payload is conjugated to the antibody using a complementary crosslinker chemistry.
Spacer arm characteristics merit careful consideration. A spacer that is too short may prevent the payload from reaching its intended binding site or target due to steric exclusion. A spacer that is too long may introduce conformational flexibility that reduces assay sensitivity or adds undesired hydrophobicity that promotes aggregation. PEG-based spacers generally improve solubility and reduce non-specific binding compared to alkyl spacers of equivalent length. For ADC applications, the spacer may also incorporate a cleavable element that releases the drug in response to intracellular conditions such as low pH, reducing potential, or protease activity.
Define the applicationResearch immunoassay, structural biology, ADC development, or biosensor construction each impose different requirements on conjugate homogeneity, stability, and scalability. Match the crosslinker chemistry to the application's tolerance for product heterogeneity.
Inventory reactive groupsCatalog the reactive groups on the antibody (lysines, cysteines, carbohydrates) and on the payload (amines, thiols, carboxylates). If no complementary pair exists, plan a derivatization step to introduce a reactive handle on one of the partners.
Choose one-step vs two-stepHomobifunctional = one-step, heterogeneous. Heterobifunctional = two-step, oriented. Zero-length = one-step but requires compatible carboxyl-amine pairs. Two-step workflows with heterobifunctional reagents generally produce cleaner products.
Evaluate spacer propertiesShort spacer (6-8 angstroms) for close coupling. Long PEG spacer (30-95 angstroms) for reducing steric hindrance. Cleavable spacer if payload release is required. Hydrophilic spacer (PEG, sulfonated) for aqueous conjugation.
Troubleshooting Crosslinking Reactions
Even carefully planned crosslinking reactions can produce unexpected results. The most common problems encountered during antibody crosslinking include aggregation, low conjugation efficiency, loss of antibody binding activity, and precipitation. Most of these issues can be traced to specific causes and resolved through systematic adjustments to the conjugation protocol.
Antibody aggregation is the most frequently reported problem. It typically results from using excessive amounts of crosslinker relative to antibody, which promotes intermolecular crosslinking between antibody molecules. Reducing the crosslinker-to-antibody molar ratio is the first corrective action. If aggregation persists, switching from a homobifunctional to a heterobifunctional crosslinker eliminates the problem by preventing antibody-antibody crosslinking in the second step. The speed of crosslinker addition also matters: adding the reagent slowly with gentle stirring, rather than as a single bolus, reduces local concentration spikes that can nucleate aggregation.
Low conjugation efficiency often stems from buffer incompatibility. Primary amines in Tris or glycine buffers consume NHS ester reagents before they can react with the antibody. Thiol-containing reducing agents such as DTT or beta-mercaptoethanol compete with antibody thiols for maleimide groups. Amine-containing buffers should be replaced with phosphate or carbonate buffer before NHS ester crosslinking. Reducing agents should be removed by desalting before maleimide-based conjugation. Additionally, some antibodies contain carrier proteins such as BSA or gelatin; these must be removed because they present abundant reactive groups that consume the crosslinker. Loss of antigen-binding activity after crosslinking suggests that reactive residues in or near the complementarity-determining regions have been modified. Switching to carbohydrate-directed or site-specific conjugation strategies that target the Fc region preserves the antigen-binding site.
AggregationReduce crosslinker-to-antibody ratio. Switch to heterobifunctional reagent with sequential addition. Add crosslinker slowly with stirring. If using homobifunctional NHS ester, consider a shorter spacer to reduce cross-antibody bridging.
Low efficiencyRemove amine-containing buffers (Tris, glycine) and thiols (DTT, mercaptoethanol) before reaction. Verify antibody concentration by A280. Remove carrier proteins. Ensure pH is within optimal range for the chosen reactive group.
Activity lossTry glycan-directed conjugation (periodate oxidation + hydrazide reagent). Use site-specific enzymatic conjugation. Reduce crosslinker molar excess. Test conjugate by ELISA or SPR to quantify residual binding activity.
PrecipitationUse sulfonated (Sulfo-) reagents for aqueous solubility. Add crosslinker dissolved in minimal DMSO volume (less than 5% final DMSO). Include mild non-ionic detergent if precipitation is surface-adsorption-related.
Crosslinking Services and Support from BOC Sciences
BOC Sciences provides custom crosslinking and bioconjugation services for antibody-based projects at research and preclinical scale. From simple antibody-fluorophore labeling to complex ADC assembly with defined linker chemistry, the conjugation team works with clients to select optimal crosslinker chemistry, optimize reaction conditions, purify and characterize the final conjugate, and deliver a ready-to-use product with documented quality metrics.
Homobifunctional crosslinkingBS3, DSS, DSG, and EGS crosslinking for antibody immobilization, protein interaction stabilization, and immunoassay development. Optimization of molar ratio to minimize aggregation and preserve antigen-binding activity.
Heterobifunctional conjugationSMCC, Sulfo-SMCC, SM(PEG)n, and photoreactive crosslinkers for oriented antibody conjugation. Two-step workflows with intermediate purification to ensure clean products with defined drug-to-antibody ratios.
Zero-length conjugationEDC/NHS coupling of carboxyl-containing payloads to antibody amines. Hapten-carrier conjugation for antibody production. Optimization of activation pH, stoichiometry, and reaction time for maximum yield.
ADC linker chemistryDesign and synthesis of cleavable and non-cleavable linkers for ADC development. Selection of heterobifunctional chemistry for cysteine, lysine, or site-specific conjugation. Analytical characterization of DAR and conjugate purity.
Need Custom Antibody Crosslinking Services?
Whether you are stabilizing a transient protein complex with homobifunctional BS3, assembling an ADC with SMCC heterobifunctional chemistry, conjugating a hapten to a carrier protein with EDC/NHS, or developing a photoreactive crosslinking protocol for interaction mapping, BOC Sciences can support your project with crosslinker selection, reaction optimization, conjugate purification, and analytical characterization.
- Homobifunctional, heterobifunctional, and zero-length crosslinking strategies
- Cleavable and non-cleavable linker design with tunable spacer length
- Photoreactive crosslinking for transient interaction capture
- Purification and QC: SEC, SDS-PAGE, DAR measurement, binding activity validation
Frequently Asked Questions About Crosslinkers in Antibody Bioconjugation
What is the difference between homobifunctional and heterobifunctional crosslinkers?
Homobifunctional crosslinkers have two identical reactive groups (e.g., two NHS esters) and conjugate two molecules bearing the same functional group in a single step. Heterobifunctional crosslinkers have two different reactive groups (e.g., an NHS ester and a maleimide) and enable sequential two-step conjugation where the antibody is first derivatized through one group and then reacted with the payload through the second group, providing greater control over conjugate architecture.
When should I use BS3 versus SMCC for antibody conjugation?
BS3 is a homobifunctional NHS ester crosslinker that reacts with amines on both the antibody and payload in a single step. It is suitable for simple one-step conjugation where some product heterogeneity is acceptable, such as antibody immobilization or protein complex crosslinking. SMCC is a heterobifunctional crosslinker with an NHS ester and a maleimide group. It is preferred when the payload contains a thiol (or can be thiol-modified) and when the goal is an oriented conjugate with controlled architecture, such as in ADC assembly or site-directed antibody labeling.
What does "zero-length" crosslinker mean?
A zero-length crosslinker activates existing functional groups to form a direct covalent bond without introducing any spacer atoms between the conjugated molecules. The most common example is EDC combined with NHS, which activates carboxyl groups for direct reaction with amines to form amide bonds. In the final conjugate, no part of the crosslinker remains, and the antibody is directly bonded to the payload. This is distinct from homobifunctional and heterobifunctional reagents, which leave a spacer arm as part of the conjugated product.
How does the spacer arm length affect conjugation outcomes?
Spacer arm length determines the physical distance between the antibody and its conjugated payload. Short spacers (6-8 angstroms) keep the payload close to the antibody and can maximize energy transfer in FRET applications but may introduce steric hindrance that reduces payload activity. Long spacers (30-95 angstroms, achieved with PEG polymers) provide greater spatial separation, reduce steric interference, and improve conjugate solubility but may introduce conformational flexibility that complicates structural analysis. The optimal spacer length depends on the size of the payload and the spatial constraints of the intended application.
What causes antibody aggregation during crosslinking and how can I prevent it?
Aggregation during crosslinking is typically caused by excessive crosslinker concentration promoting intermolecular crosslinking between antibody molecules. To prevent aggregation, reduce the crosslinker-to-antibody molar ratio, use a heterobifunctional crosslinker with sequential addition steps, add the crosslinker slowly with gentle stirring to avoid local concentration spikes, use sulfonated reagents for improved aqueous solubility, and consider purifying the activated antibody intermediate by desalting before adding the payload in the second step.
What buffers are compatible with NHS ester and maleimide crosslinkers?
NHS ester crosslinkers require amine-free buffers. Use phosphate-buffered saline (PBS), carbonate buffer (pH 8.3-8.5), borate buffer (pH 8.5), or HEPES at pH 7.2-8.5. Avoid Tris, glycine, and other primary amine-containing buffers because they consume the NHS ester. Maleimide crosslinkers require thiol-free conditions: use phosphate or HEPES buffer at pH 6.5-7.5, and remove reducing agents such as DTT, TCEP, and beta-mercaptoethanol by desalting before the maleimide reaction step.
Can photoreactive crosslinkers be used for antibody conjugation?
Yes, photoreactive heterobifunctional crosslinkers combine a chemically reactive group (NHS ester or maleimide) with a photoactivatable group (phenyl azide, benzophenone, or diazirine). The chemical group is first used to derivatize the antibody under dark conditions. After purification of the activated antibody, the conjugate is mixed with the target molecule and exposed to UV light, which triggers the photoreactive group to form a covalent bond with nearby residues. This approach is particularly useful for capturing transient antibody-antigen interactions and for mapping binding interfaces where traditional chemical crosslinking kinetics are too slow.